DK0863984T3 - Fremgangsmåder og præparater til behandling af cancer - Google Patents

Fremgangsmåder og præparater til behandling af cancer

Info

Publication number
DK0863984T3
DK0863984T3 DK96942100T DK96942100T DK0863984T3 DK 0863984 T3 DK0863984 T3 DK 0863984T3 DK 96942100 T DK96942100 T DK 96942100T DK 96942100 T DK96942100 T DK 96942100T DK 0863984 T3 DK0863984 T3 DK 0863984T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
preparations
cancer
vector
Prior art date
Application number
DK96942100T
Other languages
English (en)
Inventor
Gary L Clayman
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK0863984T3 publication Critical patent/DK0863984T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96942100T 1995-11-30 1996-11-27 Fremgangsmåder og præparater til behandling af cancer DK0863984T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US781095P 1995-11-30 1995-11-30

Publications (1)

Publication Number Publication Date
DK0863984T3 true DK0863984T3 (da) 2006-08-28

Family

ID=21728237

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96942100T DK0863984T3 (da) 1995-11-30 1996-11-27 Fremgangsmåder og præparater til behandling af cancer

Country Status (19)

Country Link
US (3) US20020077313A1 (da)
EP (1) EP0863984B1 (da)
JP (1) JP2000501394A (da)
KR (1) KR19990071795A (da)
CN (2) CN1308450C (da)
AT (1) ATE325872T1 (da)
AU (1) AU722042B2 (da)
CA (1) CA2238829A1 (da)
CZ (1) CZ296810B6 (da)
DE (1) DE69636120T2 (da)
DK (1) DK0863984T3 (da)
ES (1) ES2264145T3 (da)
HU (1) HUP9902068A3 (da)
NO (1) NO982481L (da)
NZ (1) NZ324168A (da)
PL (1) PL186018B1 (da)
RU (1) RU2174409C2 (da)
SK (1) SK70598A3 (da)
WO (1) WO1997020047A1 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348155T1 (de) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2004020971A2 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
CN1756569A (zh) * 2002-12-27 2006-04-05 印屈根治疗学股份有限公司 增生性病损中乳头瘤病毒和致癌原转化细胞的p53治疗
WO2004078987A1 (fr) * 2003-03-06 2004-09-16 Zhaohui Peng Produit de recombinaison construit a partir d'un vecteur viral et d'un gene humain suppresseur de tumeur et utilisation dudit produit de recombinaison
US20080293652A1 (en) * 2004-02-24 2008-11-27 Introgen Therapeutics, Inc. Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
CN101163984A (zh) * 2005-05-06 2008-04-16 奥索瑟夫特公司 用于跟踪对象的rf系统
US20070231304A1 (en) * 2006-01-30 2007-10-04 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
MX2010008168A (es) 2008-01-25 2011-02-24 P53 Inc Biomarcadores p53.
US8314068B2 (en) * 2008-04-14 2012-11-20 University Hospitals Of Cleveland P2X7 inhibition of epithelial cancers and papillomas
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2370582B1 (en) * 2008-12-04 2017-05-10 CuRNA, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CA3108979A1 (en) * 2009-02-02 2010-08-05 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
WO2013085624A1 (en) * 2011-12-08 2013-06-13 Virovek, Inc. Vectors harboring toxic genes, methods and uses therefor
KR102134490B1 (ko) 2012-01-12 2020-07-16 시냅틱스 인코포레이티드 단일층 용량성 이미징 센서들
WO2013123266A1 (en) * 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
AU2014236947A1 (en) 2013-03-15 2015-09-03 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MX2015013658A (es) * 2013-03-27 2016-02-18 Ge Healthcare As Metodo y reactivo para preparar una composicion diagnostica.
SG10201710528WA (en) * 2013-06-18 2018-01-30 Dnatrix Inc Treatment of brain cancer with oncolytic adenovirus
US9552089B2 (en) 2013-08-07 2017-01-24 Synaptics Incorporated Capacitive sensing using a matrix electrode pattern
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
CN104357408A (zh) * 2014-03-13 2015-02-18 哈尔滨博翱生物医药技术开发有限公司 一种重组新城疫病毒及其应用
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
WO2016050630A1 (en) 2014-09-30 2016-04-07 Universita' Degli Studi Di Brescia Antibody binding a linear epitope of human p53 and diagnostic applications thereof
EP3237452A4 (en) 2014-12-23 2018-12-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
US9778713B2 (en) 2015-01-05 2017-10-03 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
CN205028263U (zh) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 一种电容传感器
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (zh) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 单层传感器图案和感测方法
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
RU2760993C1 (ru) * 2021-02-15 2021-12-02 Сергей Александрович Никитин Способ рентгеновской терапии рака легких

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US5055400A (en) * 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US5017524A (en) * 1989-02-13 1991-05-21 Iscar Ltd. Ceramic cutting tool
US6800617B1 (en) * 1989-03-29 2004-10-05 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US6677312B1 (en) * 1989-03-29 2004-01-13 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
EP0784690B1 (en) * 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines

Also Published As

Publication number Publication date
RU2174409C2 (ru) 2001-10-10
ES2264145T3 (es) 2006-12-16
CA2238829A1 (en) 1997-06-05
PL327009A1 (en) 1998-11-09
SK70598A3 (en) 1999-04-13
US20020077313A1 (en) 2002-06-20
HUP9902068A2 (hu) 1999-10-28
CN1308450C (zh) 2007-04-04
NO982481L (no) 1998-07-29
CZ296810B6 (cs) 2006-06-14
CN101028523A (zh) 2007-09-05
WO1997020047A1 (en) 1997-06-05
US20030166603A1 (en) 2003-09-04
US20060035857A1 (en) 2006-02-16
JP2000501394A (ja) 2000-02-08
CZ165798A3 (cs) 1998-12-16
EP0863984A1 (en) 1998-09-16
CN1207771A (zh) 1999-02-10
PL186018B1 (pl) 2003-09-30
KR19990071795A (ko) 1999-09-27
AU1126397A (en) 1997-06-19
ATE325872T1 (de) 2006-06-15
AU722042B2 (en) 2000-07-20
NZ324168A (en) 2004-11-26
DE69636120D1 (de) 2006-06-14
HUP9902068A3 (en) 2001-02-28
DE69636120T2 (de) 2006-11-30
NO982481D0 (no) 1998-05-29
EP0863984B1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
DK0863984T3 (da) Fremgangsmåder og præparater til behandling af cancer
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
DK57391A (da) Hiv proteiner og peptider til anvendelse ved diagnosticering, profylakse og behandling af aids
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
DE69635931D1 (de) Komplementäre adenovirenvektorsysteme und zellinien
DK0955995T3 (da) Anvendelse af komplekser til fremstilling af præparater til behandling af sensibel hud, fremgangsmåde til fremstilling af hypoallergene præparater
NO892270L (no) Fremgangsmaate for fremstilling av preparater for anvendelse ved behandlingen av alkoholisme.
DE69630358D1 (de) Anwendung von Sulfongruppen enthaltenden Polyalkylenethern in medizinischen Materialien
NO954612L (no) Metoder og preparater for å behandle ooforektomiserte kvinner
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
HUP9901562A3 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
IL104780A0 (en) Sulfonic acid derivatives in the treatment of viral diseases
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
AU6114998A (en) Topical nifedipine preparations for the conservative treatment of functional pathologies of the anal canal
NZ503401A (en) Use of interferon-beta (IFN-B) genes for the treatment of cancer
ATE204018T1 (de) Zellwachstumsinhibitoren
IL129922A0 (en) Tissue specific expression of retinoblastoma protein
AU7674896A (en) Adenovirus-antisense k-ras expression vectors and their application in cancer therapy
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
EP0876507A4 (en) CONTROL AND CONTROL OF THE EXPRESSION OF THE PROTEIN PHOSPHATASE 2C-PP2C-ALPHA IN TUMOR CELLS IN TUMOR THERAPY, PREVENTION AND DETERMINATION
DE60008077D1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
NO980471D0 (no) Benzensulfonamidderivater, fremstilling derav og terapautiske anvendelser derav